Leukocyte-endothelial interaction in CKD

Area of Science:

• Nephrology
• Cardiology
• Immunology

Background:

• Chronic kidney disease (CKD) is a major independent risk factor for cardiovascular diseases (CVD), leading to increased cardiovascular mortality.
• Inflammation, driven by endothelial cell and innate immune system interactions, is a key link between CKD and CVD.
• CKD-induced uremic toxins cause vascular injury, endothelial dysfunction, and immune system activation, exacerbating CVD risk.

Purpose of the Study:

• To explore the role of inflammation in the CKD-CVD link.
• To investigate CKD-associated changes in monocytes and their impact on endothelial dysfunction.
• To highlight the significance of the NLRP3-IL-1β-IL-6 pathway in CKD and CVD pathogenesis.

Main Methods:

• Review of recent studies on CKD, CVD, inflammation, and immune system interactions.
• Analysis of the role of uremic toxins in vascular injury and endothelial dysfunction.
• Examination of the NLRP3-IL-1β-IL-6 signaling pathway in CKD and CVD.

Main Results:

• CKD promotes vascular inflammation and endothelial dysfunction through metabolic changes and uremic toxins.
• Monocyte alterations in CKD contribute to endothelial dysfunction, worsening CKD and associated CVD.
• The NLRP3-IL-1β-IL-6 pathway is critically involved in the progression of both CKD and CVD.

Conclusions:

• Targeted anti-inflammatory therapies, particularly inhibiting the NLRP3-IL-1β-IL-6 pathway, show potential for managing CKD-associated CVD.
• CKD patients with nonresolving inflammation could significantly benefit from novel anti-inflammatory strategies.
• Current therapeutic regimens have limited efficacy for CKD patients, underscoring the need for new approaches.